Singapore Clinical Trial: A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Posted On: 2026-05-01

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)'. The following are the other relevant details related to the trial:

Therapeutic Area: Rheumatology

Trial Centre(s): National University Hospital Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Julian Lim Wen Wei Dr Andrea Low

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Singapore Clinical Trial: A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)